Clinical data reveals how a targeted oral probiotic can deliver a breakthrough solution to a common problem—bad breath during orthodontic treatment.
Halitosis is an often-overlooked yet highly disruptive side effect for people wearing braces. With up to 50% of the global population undergoing orthodontic treatment at some stage in life, there’s a growing demand for non-invasive, scientifically credible solutions that go beyond traditional hygiene methods.
In this whitepaper, BLIS Technologies presents in-vitro and clinical trial evidence demonstrating how BLIS M18™, a precision probiotic strain of Streptococcus salivarius, effectively reduces volatile sulphur compounds (VSCs)—the primary cause of bad breath in orthodontic patients.
Whether you’re developing new product formats or looking to differentiate with clinically validated oral care innovations, this is essential reading for formulators, brand leaders, and healthcare partners.
What You’ll Learn:
- The microbial mechanism behind halitosis in braces wearers
- Clinical study results showing sustained reduction in VSCs post-intervention
- How BLIS M18™ complements oral hygiene by targeting the root microbial cause
- Opportunities for product innovation using a science-led, strain-specific probiotic
